ArticleMolecular biology reports2026
Caffeic acid phenethyl ester attenuates phenotypic switching and inflammation in abdominal aortic aneurysm via the NF-κB pathway.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn our previous animal experiments, we found that caffeic acid phenethyl ester (CAPE) inhibited the early formation of elastase-induced abdominal aortic aneurysms (AAA) in rats. However, its efficacy in the angiotensin II (Ang II)-induced AAA model and the underlying mechanism remain unclear. Therefore, the primary aim of this study was to further validate the potential mechanism of CAPE through in vivo and in vitro experiments utilizing Ang II. METHODS AND
resultsApoE
conclusionsCAPE mitigates the progression of AAA in mice and counteract the abnormal cell phenotype and inflammatory responses in Ang II-stimulated MOVAS cells. These protective effects might be achieved by inhibiting the NF-κB pathway.
Indexed as
Identifiers
42113350What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.